跳至主要内容
临床试验/ACTRN12607000074493
ACTRN12607000074493已完成3 期

An investigation of the effects of n-acetyl cysteine in bipolar disorder based on time to intervention for mood symptoms and a range of psychiatric rating scales.

Stanley Medical Research Institute0 个研究点目标入组 150 人开始时间: 2007年1月23日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 ot stated(—)
性别
All

入选标准

  • Meeting Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for bipolar disorder, have current symtpoms of depression with a Montgomery-Asberg Depression Rating Scale (MADRS) score over 12 at baseline, have the capacity to consent, be on stable therapy for at least one month prior to randomisation.

排除标准

  • Individuals with a known or suspected clinically relevant medical disorder, elderly individuals with respiratory insufficiency, individuals who are pregnant or lactating, individuals currently taking greater than 500 mg/day of NAC, 200 ug of slenium/day or 500 International Units (IU) of vitamin E/day, individuals who have had previous anaphylactic reactions to NAC or any component of the preparation.

研究者

发起方
Stanley Medical Research Institute

相似试验